A number of observational studies have shown an inverse association between circulating 25-hydroxyvitamin D and total mortality, but a reverse J-shaped association has also been reported. In a large nested case-control study, serum-25-hydroxyvitamin D (s-25(OH)D) was positively associated with incident prostate cancer.
Based on the same study population, the primary aim of the present study was to investigate the association between s-25(OH)D and total mortality.
Men participating in population based health screenings during 1981-1991 and enrolled in a nested case-control study were followed throughout 2007 with respect to all-cause and cause-specific mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox proportional hazards regression.
In men with prostate cancer (n = 2282), there was a significant inverse association between s-25(OH)D and total mortality after controlling for potential confounders (HR = 1.25 (95% CI 1.05-1.50), s-25(OH)D
In this study population, s-25(OH)D was inversely associated with total mortality during more than two decades of follow-up, despite, as previous reported, high s-25(OH)D was associated with increased risk of prostate cancer.
PloS one. 2016 Mar 17*** epublish ***
Haakon E Meyer, Nathalie C Støer, Sven O Samuelsen, Rune Blomhoff, Trude E Robsahm, Magritt Brustad, Edward L Giovannucci, Tone Bjørge
Department of Community Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway., Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway., Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., The Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway., Department of Community Medicine, UIT The Artic University of Norway, Tromsø, Norway., Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America., The Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway.